



NATIONAL
QUALITY FORUM

Opioid Technical Expert Panel Web Meeting 3

Michael Abrams, MPH, PhD
Samuel Stolpe, PharmD, MPH
Poonam Bal, MHSA
Vaishnavi Kosuri, MPH

June 4, 2019

Agenda

- Objectives
- Environmental Scan Draft Report
 - ▣ *Purpose*
 - ▣ *Methodology*
 - ▣ *Results*
- Opportunity for Public Comment
- Next Steps

Committee Members

- Jeff Schiff, MD, MBA - **Co-chair**
- Brandon Marshall, PhD - **Co-chair**
- Anika Alvanzo, MD, MS
- Michael Ashburn, MD, MPH, MBA
- Antje Barreveld, MD
- Patty Black, BS
- Jeannine Brant, PhD, APRN, AOCN, FAAN
- Caroline Carney, MD, MSc, FAMP, CPHQ
- Anthony Chiodo, MD, MBA
- Jettie Eddleman, BSN, RN
- Maria Foy, PharmD, BCPS, CDE
- Jonathan Gleason, MD
- Anita Gupta, DO, PharmD, MPP
- Mark Hurst, MD
- Katie Jordan, OTD, OTR/L
- Navdeep Kang, PsyD
- Sarah Melton, Pharm D, BCPP, BCACP, FASCP
- Gary Mendell, MBA
- Darlene Petersen, MD
- Laura Porter, MD
- James Rhodes, PharmD, MBA, BCPS, BCGP
- Darshak Sanghavi, MD
- Evan Schwarz, MD, FACEP, FACMT
- Norris Turner, PharmD, PhD
- Sarah Wakeman, MD, FASEM
- Sarah Wattenberg, MSW
- Arthur Robin Williams, MD
- Bonnie Zickgraf, BSN, RN, CMCN

Federal Liaisons

- Robert Anthony, **ONC**
- Sarah Duffy, PhD, **NIH/NIDA**
- Elisabeth Kato, MD, MRP, **AHRQ**
- SreyRam Kuy, MD, MHS, FACS, **VA**
- Scott Smith, PhD, **ASPE**
- Judith Steinberg, MD, MPH, **HRSA**
- Linda Streitfeld, MPH, **CMMI**

Environmental Scan

Key Questions

- Existing measures (fully developed)?
- Measure concepts (in-development measures)?
- Future directions, including ideas and “gaps”

Organizational Domains/Ideas from TEP

Prevention (includes “twin” emphasis on SUD prevention and pain management)

- Prescription monitoring
- Perioperative management across conditions
- Suicidal risks correlating with pain
- Opioid naïve consumers who develop SUDs
- Tapering opioid analgesia
- Supply side (illicit or prescription) - somewhat de-emphasized

Organizational Domains/Ideas from TEP

SUD treatment

- Comorbidities: physical and psychiatric, e.g., hepC and depression; pain, sleep/respiratory disorders; risks
- Recovery (chronic condition, i.e., not just expectation of uninterrupted abstinence)
- Functional assessments, including those related quality of life of life issues (e.g., self- and demonstrated efficacy/productivity; employment)
- Quality of life (consumer satisfaction)
- Access: financial and otherwise, referral issues, Data 2000 waiver
- Venue quality: EDs (include urgent care), other centers of treatment from locations of brief intervention to more intensive SUD treatment centers

Organizational Domains/Ideas from TEP

Harm Reduction

Interdiction → “Criminal justice issues,” with emphasis on treatment

- Interpersonal violence
- Jail involvement

Ancillary issues

- Alternative therapies for pain (e.g., physical activity)
- Perinatal issues
- Tobacco

Key informants

- Consumer perspective

Organizational Domains/Ideas from TEP

Relevant state laws

- Utah - OD death chart reviews
- Louisiana - targeting pernicious opioid prescribing
- Missouri - restricting syringe access
- Massachusetts - quantity limits
- Maryland - Medication treatment availability in jails

Environmental Scan Summary

- Themes
- Gaps

Committee Discussion

Discussion Questions

- What are your overall impressions of the environmental scan?
 - ▣ *What, if anything, seems to be missing from this report?*
 - ▣ *What, if anything, seems superfluous to the report?*
 - ▣ *Is this document shaping up as a useful tool for you to ponder gaps and future directions regarding quality of care measurement related to the U.S. opioid overdose epidemic?*
- What conclusions/interpretations does the environmental scan point towards?
 - ▣ *Surprise contemporary, opportunities (i.e., existing measures)?*
 - ▣ *Highest priority “gaps” or future directions?*

Opportunity for Public Comment

Next Steps

Timeline	
15-Day Comment Period	July 12 – July 26, 2019
Web Meeting 4	August 13, 2019
Final Environmental Scan	September 6, 2019
Web Meeting 5	September 16, 2019
Web Meeting 6	October 10, 2019
30-Day Comment Period	December 6, 2019 – January 6, 2020
Web Meeting 7	January 21, 2020
Final Report	February 6, 2020

Project Information

- Email: opioid@qualityforum.org
- Phone: 202-783-1300
- Project page
[https://www.qualityforum.org/Opioid and Opioid Use Disorder TEP.aspx](https://www.qualityforum.org/Opioid_and_Opioid_Use_Disorder_TEP.aspx)
- SharePoint page
<http://share.qualityforum.org/Projects/Opioid%20TEP/SitePages/Home.aspx>